long intergenic non-protein coding RNA 2535Genealiases: []
Q-omics provides the consensus-scored LINC02535 profile across patient tissues and cancer cell-line models. LINC02535 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02535 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, LINC02535 RNA expression shows 12,646 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where LINC02535 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02535 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02535 survival associations across molecular data types. LINC02535 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02535 RNA expression–survival associations across cancer types. High LINC02535 expression shows unfavorable associations in HNSC, KIRP, MESO, LIHC, LUAD and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02535 RNA expression.
This table summarizes LINC02535 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02535. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02535 shows lower tumor expression in KICH and higher tumor expression in HNSC, THCA, LUAD, STAD and LUSC. The HNSC box plot shows higher LINC02535 RNA expression in tumor versus normal tissue (log2 FC = +0.657, t-test p < 0.001).
This table shows molecular features associated with LINC02535 in patient tissues and cancer cell lines. In patient samples, LINC02535 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
